Research programme: gold nanoparticle based therapy - Oraya Therapeutics

Drug Profile

Research programme: gold nanoparticle based therapy - Oraya Therapeutics

Alternative Names: Gold nanoparticles - Oraya Therapeutics

Latest Information Update: 01 Dec 2014

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Oraya Therapeutics
  • Developer Dana-Farber Cancer Institute; Oraya Therapeutics
  • Class Heavy metals
  • Mechanism of Action Angiogenesis inhibitors; Cell death stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Research Wet age-related macular degeneration

Most Recent Events

  • 05 Aug 2014 Oraya Therapeutics receives Small Business Technology Transfer grant from NIH for the development of gold nanoparticles in Wet age-related macular degeneration
  • 05 Aug 2014 Early research in Wet age-related macular degeneration in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top